腹膜游离癌细胞会对胃癌的疾病进展和患者预后产生负面影响。本研究旨在探讨利用黄金角径向采样动态对比增强磁共振成像（GRASP DCE-MRI）预测胃癌患者腹膜游离癌细胞存在的可行性。所有入组患者连续分为分析组和分析组。验证组。对接受手术的胃癌患者进行术前磁共振成像（MRI）扫描和灌注，并采集腹腔灌洗标本进行检查。根据腹腔灌洗细胞学（PLC）结果，将患者分为灌洗液阴性组和阳性组。收集的数据包括临床和磁共振信息。构建列线图预测模型预测腹腔灌洗液阳性率，并根据验证组数据验证模型的有效性。GRASP DCE-预测的PLC阳性病例比例差异无统计学意义MR和实际PLC测试。 MR 肿瘤分期、肿瘤厚度和灌注参数 Tofts-Ketty 模型体积转移常数 (Ktrans) 是腹膜灌洗液阳性的独立预测因子。列线图模型的建模组和验证组的一致性指数（C 指数）分别为 0.785 和 0.742。GRASP DCE-MR 可以有效预测胃癌患者的腹膜游离癌细胞。使用这些预测因子构建的列线图模型可以帮助临床医生更好地预测胃癌患者中存在腹膜游离癌细胞的风险。

Peritoneal free cancer cells can negatively impact disease progression and patient outcomes in gastric cancer. This study aimed to investigate the feasibility of using golden-angle radial sampling dynamic contrast-enhanced magnetic resonance imaging (GRASP DCE-MRI) to predict the presence of peritoneal free cancer cells in gastric cancer patients.All enrolled patients were consecutively divided into analysis and validation groups. Preoperative magnetic resonance imaging (MRI) scans and perfusion were performed in patients with gastric cancer undergoing surgery, and peritoneal lavage specimens were collected for examination. Based on the peritoneal lavage cytology (PLC) results, patients were divided into negative and positive lavage fluid groups. The data collected included clinical and MR information. A nomogram prediction model was constructed to predict the positive rate of peritoneal lavage fluid, and the validity of the model was verified based on data from the verification group.There was no statistical difference between the proportion of PLC-positive cases predicted by GRASP DCE-MR and the actual PLC test. MR tumor stage, tumor thickness, and perfusion parameter Tofts-Ketty model volume transfer constant (Ktrans) were independent predictors of positive peritoneal lavage fluid. The nomogram model featured a concordance index (C-index) of 0.785 and 0.742 for the modeling and validation groups, respectively.GRASP DCE-MR could effectively predict peritoneal free cancer cells in gastric cancer patients. The nomogram model constructed using these predictors may help clinicians to better predict the risk of peritoneal free cancer cells being present in gastric cancer patients.